Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | March 14, 2026 | March 17, 2026 |
| Dare Bioscience, Inc.DARE · Entity 7799 | Director | June 21, 2023 | June 22, 2023 |
| Neuronetics, Inc.STIM · Entity 6248 | Director | May 26, 2020 | May 28, 2020 |
| SeaSpine Holdings CorpSPNE · Entity 120832 | Director | May 30, 2018 | May 31, 2018 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date March 14, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 258,788 |
Ending reported balance
After 2026-03-15 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-03-14 · Exercise / conversion · Acquired 24,519 · Balance 235,969 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Row 2 · 2026-03-14 · Grant · Acquired 24,520 · Balance 260,489 F2: On March 14, 2025, the Reporting Person was granted 73,559 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award. Row 3 · 2026-03-14 · Tax withholding · Disposed 14,728 · Balance 245,761 F3: Reflects an aggregate of 14,728 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026. Row 4 · 2026-03-15 · Exercise / conversion · Acquired 25,131 · Balance 270,892 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Row 5 · 2026-03-15 · Tax withholding · Disposed 12,104 · Balance 258,788 F4: Reflects an aggregate of 12,104 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 49,040 |
Reported balance
After 2026-03-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-14 · Exercise / conversion · Disposed 24,519 · Balance 49,040 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F6: On March 14, 2025, the Reporting Person was granted 73,559 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 25,132 |
Reported balance
After 2026-03-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-15 · Exercise / conversion · Disposed 25,131 · Balance 25,132 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F7: On March 15, 2024, the Reporting Person was granted 75,395 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award. |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 11,742 |
Reported balance
Holding disclosure · report date 2026-03-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,742 F5: Consists of shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which the Reporting Person is a beneficiary and the sole trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
F2: On March 14, 2025, the Reporting Person was granted 73,559 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.
F3: Reflects an aggregate of 14,728 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.
F4: Reflects an aggregate of 12,104 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.
F5: Consists of shares held by The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which the Reporting Person is a beneficiary and the sole trustee.
F6: On March 14, 2025, the Reporting Person was granted 73,559 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.
F7: On March 15, 2024, the Reporting Person was granted 75,395 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.
Dare Bioscience, Inc.
Report date June 21, 2023 · Filed June 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2033-06-21 | Direct | 40,000 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 40,000 · Balance 40,000 F1: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.
Neuronetics, Inc.
Report date May 26, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,437 |
Reported balance
After 2020-05-26 transaction · row 1
1 source rowRow 1 · 2020-05-26 · Grant · Acquired 30,000 · Balance 34,437 F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock
SeaSpine Holdings Corp
Report date May 30, 2018 · Filed May 31, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,948 |
Reported balance
After 2018-05-30 transaction · row 1
1 source rowRow 1 · 2018-05-30 · Grant · Acquired 8,857 · Balance 28,948 F1: The restricted stock award vests in full on May 30, 2019, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock award vests in full on May 30, 2019, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting.
Xilio Therapeutics, Inc.
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.40 · Expires 2036-04-14 | Direct | 10,000 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 10,000 · Balance 10,000 F1: The option was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vigil Neuroscience, Inc.
Report date August 05, 2025 · Filed August 05, 2025
Section 16 reporting ended · disclosed 2025-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 1
1 source rowRow 1 · 2025-08-05 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F2: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-05 · Disposition to issuer · Disposed 24,761 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-05 · Disposition to issuer · Disposed 24,984 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.02 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-05 · Disposition to issuer · Disposed 36,690 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-08-05 · Disposition to issuer · Disposed 18,068 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-08-05 · Disposition to issuer · Disposed 13,928 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-08-05 · Disposition to issuer · Disposed 5,017 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-08-05 · Disposition to issuer · Disposed 12,155 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
| Stock Option Award (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 | Direct | 0 |
Reported balance
After 2025-08-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-08-05 · Disposition to issuer · Disposed 6,432 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").
F2: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 13, 2024 00:04 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 6,973 | $25.42 | $177,253.66 |
DisclosureSEC source: 0001171843-24-001307 · ownership.xml · nonDerivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,641 F3 · shares: Reflects an aggregate of 6,973 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024. F4 · price: Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:04 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 14,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001307 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 152 shares purchased on May 12, 2023 and 787 shares purchased on November 14, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:57 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | GrantStock Option Grant (Right to Buy) · Derivative | 24,761 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0000950170-24-026413 · ownership.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,761 Underlying: Common Stock · 24,761 shares Expires 2034-03-01 F1 · derivative.exercise_date: This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2024. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 01:48 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001401914-23-000038 · wk-form4_1687398491.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:10 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | GrantStock Option Grant (Right to Buy) · Derivative | 13,928 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015166 · doc4.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,928 Underlying: Common Stock · 13,928 shares Expires 2033-06-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 24,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-002685 · ownership.xml · derivative · entry 4 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 10,900 | $26.34 | $287,106.00 |
DisclosureSEC source: 0001171843-23-002685 · ownership.xml · nonDerivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,255 F2 · shares: Reflects an aggregate of 10,900 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on April 26, 2023. F3 · price: Reflects the closing price of ANIK common stock on April 26, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 24,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-002685 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on April 26, 2020. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 30,060 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001684 · ownership.xml · derivative · entry 4 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,119 Underlying: Common Stock · 30,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 13,211 | $26.10 | $344,807.10 |
DisclosureSEC source: 0001171843-23-001684 · ownership.xml · nonDerivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,580 F2 · shares: Reflects an aggregate of 13,211 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2023. F3 · price: Reflects the closing price of ANIK common stock on March 10, 2023, the trading day immediately preceding the date on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 30,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001684 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 11, 2022. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 14,419 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001595 · ownership.xml · derivative · entry 6 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,420 Underlying: Common Stock · 14,419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F9 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 130,998 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001171843-23-001595 · ownership.xml · derivative · entry 5 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,998 Underlying: Common Stock · 130,998 shares Expires 2033-03-09 F7 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F8 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 60,004 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001595 · ownership.xml · derivative · entry 4 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,004 Underlying: Common Stock · 60,004 shares Expires not disclosed F6 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F6 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 4,232 | $26.91 | $113,883.12 |
DisclosureSEC source: 0001171843-23-001595 · ownership.xml · nonDerivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,731 F3 · shares: Reflects an aggregate of 4,232 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2023. F4 · price: Reflects the closing price of ANIK common stock on March 9, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 14,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001595 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 540 shares purchased on May 13, 2022 and 178 shares purchased on November 14, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:08 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | GrantStock Option Grant (Right to Buy) · Derivative | 6,432 | $7.62 Strike: $11.87 | $48,998.98 |
DisclosureSEC source: 0000899243-23-007021 · doc4.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,432 Underlying: Common Stock · 6,432 shares Expires 2033-03-01 F1 · price: This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2023. F1 · derivative.exercise_date: This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2023. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:18 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001401914-22-000060 · wf-form4_165610191903120.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common stock · 38,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:05 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | GrantStock Option Grant (Right to Buy) · Derivative | 12,155 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0000899243-22-022158 · doc4.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,155 Underlying: Common Stock · 12,155 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 9, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 24,576 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-002980 · ownership.xml · derivative · entry 3 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,575 Underlying: Common Stock · 24,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. F3 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 24,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-002980 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on April 26, 2020. The 24,576 shares resulting from the RSU vest were retained in full as a result of Dr. Blanchard's election to pay cash to cover the applicable taxes resulting from the RSU vest. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 13:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 3,813 | $25.81 | $98,428.78 |
DisclosureSEC source: 0001171843-22-001833 · ownership.xml · nonDerivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,992 F2 · price: On March 11, 2022, Dr. Blanchard purchased 3,813 shares in multiple trades ranging from $25.70 to $25.94. The price reported above reflects the weighted average purchase price. Dr. Blanchard undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 13:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 4,287 | $25.36 | $108,714.03 |
DisclosureSEC source: 0001171843-22-001833 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,179 F1 · price: On March 11, 2022, Dr. Blanchard purchased 4,287 shares in multiple trades ranging from $24.69 to $25.69. The price reported above reflects the weighted average purchase price. Dr. Blanchard undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:00 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 208,821 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001171843-22-001903 · ownership.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,821 Underlying: Common Stock · 208,821 shares Expires 2032-03-11 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 11, 2023. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:00 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 90,179 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001903 · ownership.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,179 Underlying: Common Stock · 90,179 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:35 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 14,420 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001809 · ownership.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,839 Underlying: Common Stock · 14,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F2 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:35 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 14,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001809 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. The 14,420 shares resulting from the RSU vest were retained in full as a result of Dr. Blanchard's election to pay cash to cover the applicable taxes resulting from the RSU vest. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:05 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | GrantStock Option Grant (Right to Buy) · Derivative | 5,017 | $9.63 Strike: $16.13 | $48,313.71 |
DisclosureSEC source: 0000899243-22-009053 · doc4.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,017 Underlying: Common Stock · 5,017 shares Expires 2032-03-01 F1 · price: This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022. F1 · derivative.exercise_date: This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022. Read SEC document |
| June 24, 2021 Filed Jun 24, 2021 20:43 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001401914-21-000094 · wf-form4_162456741352719.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common stock · 30,000 shares Expires 2031-06-24 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,994 | $0.00 Strike: $33.40 | $0.00 |
DisclosureSEC source: 0001171843-21-004397 · ownership.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,644 Underlying: Common Stock · 2,994 shares Expires 2030-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning on April 26, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,994 | $33.40 | $99,999.60 |
DisclosureSEC source: 0001171843-21-004397 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 21:00 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 24,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-002890 · ownership.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,151 Underlying: Common Stock · 24,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. F2 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 21:00 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 24,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-002890 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the first vesting installment of RSUs granted on April 26, 2020. The 24,575 shares resulting from the RSU vest were retained in full as a result of Dr. Blanchard's election to pay cash to cover the applicable taxes resulting from the RSU vest. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:08 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 108,398 | $0.00 Strike: $37.40 | $0.00 |
DisclosureSEC source: 0001171843-21-001708 · ownership.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,398 Underlying: Common Stock · 108,398 shares Expires 2031-03-09 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 9, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:08 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 43,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-001708 · ownership.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,259 Underlying: Common Stock · 43,259 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| June 25, 2020 Filed Jun 27, 2020 00:56 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001401914-20-000097 · wf-form4_159321937668046.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common stock · 22,500 shares Expires 2030-06-25 F1 · derivative.exercise_date: This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:21 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000403 · edgar.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,437 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 22:41 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 104,638 | $0.00 Strike: $33.40 | $0.00 |
DisclosureSEC source: 0001171843-20-002971 · ownership.xml · derivative · entry 4 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,638 Underlying: Common Stock · 104,638 shares Expires 2030-04-26 F5 · derivative.exercise_date: The stock options vest in three equal annual installments beginning April 26, 2021. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 22:41 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 73,726 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-002971 · ownership.xml · derivative · entry 3 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,726 Underlying: Common Stock · 73,726 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 22:41 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,794 | $33.40 | $59,919.60 |
DisclosureSEC source: 0001171843-20-002971 · ownership.xml · nonDerivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,903 F2 · security: Reflects an aggregate of 1,794 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on April 26, 2020. F3 · price: Reflects the closing price of the ANIK common stock on April 26, 2020, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 22:41 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 4,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-002971 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director · President, CEO, Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the vesting of RSUs granted on February 25, 2020 in accordance with the terms of Dr. Blanchard's agreement with the Company related to her appointment as its interim Chief Executive Officer. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:48 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 4,231 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001357 · ownership.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,231 Underlying: Common Stock · 4,231 shares Expires not disclosed F1 · derivative.exercise_date: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). "Term" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO. F1 · derivative.expiration_date: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). "Term" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 00:55 UTC | Dare Bioscience, Inc. DARE · Entity 7799 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001401914-19-000100 · wf-form4_157438410017998.xml · derivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 45,000 shares Expires 2029-11-20 F1 · derivative.exercise_date: This option vests as to 1/3rd of the shares subject to this option on each of the first three anniversaries of the transaction date, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:47 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantStock Option (right to buy) · Derivative | 7,347 | $0.00 Strike: $13.43 | $0.00 |
DisclosureSEC source: 0001209191-19-033450 · doc4.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,347 Underlying: Common Stock · 7,347 shares Expires 2029-05-27 F3 · derivative.exercise_date: The option shall vest on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:47 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 3,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033450 · doc4.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,437 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001383 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,466 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:19 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantStock Option (right to buy) · Derivative | 1,453 | $0.00 Strike: $17.45 | $0.00 |
DisclosureSEC source: 0001192482-19-000087 · edgar.xml · derivative · entry 2 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,453 Underlying: Common Stock · 1,453 shares Expires 2029-02-13 F3 · derivative.exercise_date: The stock options will vest on the earlier of the first anniversary of the date of grant and the date of the Issuer's next annual meeting of stockholders, subject to the the Reporting Person's continued service. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:19 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000087 · edgar.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 F1 · security: Granted in the form of restricted stock units. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units will vest on the earlier of the first anniversary of the date of grant and the date of the Issuer's next annual meeting of stockholders, subject to the the Reporting Person's continued service. F1 · price: Granted in the form of restricted stock units. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 20:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-006411 · ownership.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,624 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest immediately prior to the Anika Therapeutics, Inc. 2019 Annual Meeting of Stockholders. Read SEC document |
| May 30, 2018 Filed May 31, 2018 20:54 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 8,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-18-000097 · wf-form4_152779999647939.xml · nonDerivative · entry 1 Blanchard Cheryl R · CIK 0001326530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,948 F1 · shares: The restricted stock award vests in full on May 30, 2019, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.